Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CCND1 amplification

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

CCND1 amplification	Melanoma	CCND1 amplification	Melanoma	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B	sorafenib Sensitive: B - Late Trials sorafenib Sensitive : B
CCND1 amplification	Estrogen Receptor Positive Breast Cancer	CCND1 amplification	Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
CCND1 amplification	Solid Tumor	CCND1 amplification	Solid Tumor	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
CCND1 amplification	Breast Cancer	CCND1 amplification	Breast Cancer	Aromatase inhibitor Resistant: C3 – Early Trials Aromatase inhibitor Resistant : C3	Aromatase inhibitor Resistant: C3 – Early Trials Aromatase inhibitor Resistant : C3
CCND1 amplification	Melanoma	CCND1 amplification	Melanoma	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3
CCND1 amplification	Lung Non-Small Cell Squamous Cancer	CCND1 amplification	Lung Non-Small Cell Squamous Cancer	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
CCND1 amplification	Melanoma	CCND1 amplification	Melanoma	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3
CCND1 amplification	Head and Neck Cancer	CCND1 amplification	Head and Neck Cancer	cetuximab + palbociclib Sensitive: C3 – Early Trials cetuximab + palbociclib Sensitive : C3	cetuximab + palbociclib Sensitive: C3 – Early Trials cetuximab + palbociclib Sensitive : C3
CCND1 amplification	Squamous Cell Carcinoma of Head and Neck	CCND1 amplification	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: C4 – Case Studies cetuximab Sensitive : C4	cetuximab Sensitive: C4 – Case Studies cetuximab Sensitive : C4
CCND1 amplification	Breast Cancer	CCND1 amplification	Breast Cancer	lapatinib Sensitive: D – Preclinical lapatinib Sensitive : D	lapatinib Sensitive: D – Preclinical lapatinib Sensitive : D